Immune thrombocytopenic purpura
ICD-10 D69.3 · ICD-11 3B64.10

Treatment of Immune Thrombocytopenic Purpura in Children Under 18 with Mucosal Bleeding or Diminished Quality of Life

Clinical Scenario

This protocol applies to children under 18 years of age who have newly diagnosed immune thrombocytopenic purpura (ITP) presenting with non-life-threatening mucosal bleeding and/or diminished health-related quality of life. The paediatric age group and symptom profile together define the specific treatment context addressed here.

First-Line Treatment Overview (partial)

For children in this scenario, a short course of corticosteroid therapy is the recommended first-line approach. When corticosteroids are contraindicated or not preferred, the guidelines specify alternative therapeutic options. The full evidence-based regimen — including agent selection, criteria for alternatives, and clinical sequencing — is available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens
References
  1. In children with newly diagnosed ITP who have non-life-threatening mucosal bleeding and/or diminished health-related quality of life, the ASH guideline panel suggests corticosteroids rather than intravenous immunoglobulin or anti-D immunoglobulin.
  2. For patients where corticosteroids are contra-indicated or otherwise not preferred, the ASH guideline panel suggests either intravenous immunoglobulin or anti-D immunoglobulin.
  3. In children with newly diagnosed ITP who have non-life-threatening mucosal bleeding and/or diminished health related quality of life, the ASH guideline panel recommends against courses of corticosteroids longer than 7 days in favor of courses 7 days or shorter.
View source ↗